These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23334122)

  • 1. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients.
    Shi X; Zhang X; Yi C; Wang X; Chen Z; Zhang B
    Clin Nucl Med; 2013 Feb; 38(2):98-102. PubMed ID: 23334122
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of 13N-ammonia and 18F-FDG PET/CT in the identification of metabolic phenotype of primary human brain tumors.
    Yi C; Shi X; Yu D; Luo G; Zhang B; He Q; Zhang X
    Nuklearmedizin; 2019 Jun; 58(3):272-278. PubMed ID: 30995685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas.
    Shi X; Liu Y; Zhang X; Yi C; Wang X; Chen Z; Zhang B
    Clin Nucl Med; 2013 Jul; 38(7):522-6. PubMed ID: 23698463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess.
    Shi X; Yi C; Wang X; Zhang B; Chen Z; Tang G; Zhang X
    Clin Nucl Med; 2015 Mar; 40(3):195-9. PubMed ID: 25546194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
    Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
    Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET.
    Uchinomura S; Mitamura K; Norikane T; Yamamoto Y; Oishi A; Hatakeyama T; Miyake K; Nishiyama Y
    Nucl Med Commun; 2022 Mar; 43(3):270-274. PubMed ID: 34864812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.
    Kawai N; Okubo S; Miyake K; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
    Ann Nucl Med; 2010 Jun; 24(5):335-43. PubMed ID: 20379859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
    Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
    Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT.
    Khangembam BC; Karunanithi S; Sharma P; Kc SS; Kumar R; Julka PK; Kumar R; Bal C
    Neuroradiology; 2014 Oct; 56(10):893-902. PubMed ID: 24989883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
    Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer.
    Yi C; Yu D; Shi X; Zhang X; Luo G; He Q; Zhang X
    Nucl Med Commun; 2016 Mar; 37(3):239-46. PubMed ID: 26588068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative and Visual Characteristics of Primary Central Nervous System Lymphoma on
    Liu D; Kong Z; Wang Y; Chen W; Wang Y; Chen W; Liu L; Dang Y; Ma W; Wang Y; Cheng X
    Interdiscip Sci; 2019 Jun; 11(2):300-306. PubMed ID: 31264053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
    Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
    Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of suprasellar meningiomas from non-functioning pituitary macroadenomas by
    Ding L; Zhang F; He Q; Li Z; Shi X; Li R; Zhang X
    BMC Cancer; 2020 Jun; 20(1):564. PubMed ID: 32552842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
    Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
    Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
    Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
    World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [
    Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
    Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.